Will we see another Cap Raise before the 4C is out?, page-23

We still have feesability trials for US and then registration trials for the EU and FDA before anyone can sell anything. One step at a time.

IMO some of your assumptions are off the mark.

Ramping up production is not “easy” and without cost.
We are still only barely known as Doctors generally only concern themselves with “approved” devices so still a long way to go in marketing.
Piper Sandler is an essential part of the team to ensure if M&A happens it is in the best interest of shareholders. As shareholders we cannot decide when M&A occurs but as a company we can be prepared. (Remember we have already had one low ball offer from a major prior to FIH results) This is smart and sends an early message that what we have is very valuable, a serious device in TAVR and that we won’t be push overs.

Going it alone is definitely a possibility but I doubt the other interested parties will let it happen. It is harder than most think to dislodge two gorillas with almost 100% market share between them. A partnership would almost be the perfect outcome.

However, if we do go it alone that would be a good outcome also as our results will allow us to more easily raise the capital required at higher prices. We then be acquired later for much more.

At the end of the day I think all shareholders will do well from here whether we go it alone, get acquired or partner.

We still have results to come, lost of news flow ahead, cash in the bank and the market is starting to take notice.

Just IMO DYOR and Not advice.